{"id":"tace-regimen","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Post-embolization syndrome (fever, abdominal pain, nausea)"},{"rate":"30-50","effect":"Hepatic dysfunction/elevated transaminases"},{"rate":"10-30","effect":"Ascites"},{"rate":"5-15","effect":"Encephalopathy"},{"rate":"2-5","effect":"Bleeding/hematoma at puncture site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TACE combines chemotherapy infusion with embolization of the feeding blood vessel to the tumor, creating a dual mechanism of drug delivery and ischemic necrosis. The procedure selectively targets tumor vasculature while minimizing systemic exposure. This approach is particularly effective for intermediate-stage hepatocellular carcinoma where the tumor burden is too extensive for surgical resection but the liver function remains adequate.","oneSentence":"TACE (transarterial chemoembolization) is a locoregional therapy that delivers chemotherapy directly to hepatocellular carcinoma tumors via the hepatic artery while simultaneously blocking blood supply to the tumor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:22.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma, intermediate stage (BCLC stage B)"},{"name":"Hepatocellular carcinoma, advanced stage (BCLC stage C) as bridge or palliative therapy"}]},"trialDetails":[{"nctId":"NCT07489976","phase":"PHASE2","title":"IIT2025-03-YANG-LIFT-HCC","status":"RECRUITING","sponsor":"Ju Dong Yang","startDate":"2026-04-01","conditions":"Hepato Cellular Carcinoma","enrollment":41},{"nctId":"NCT06071052","phase":"PHASE2","title":"TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-12-01","conditions":"Liver Metastasis Colon Cancer","enrollment":21},{"nctId":"NCT07417800","phase":"NA","title":"Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"Hepatocellular Carcinoma (HCC), Artificial Intelligent, Adjuvant Chemoradiotherapy","enrollment":1000},{"nctId":"NCT07417397","phase":"PHASE3","title":"Adjuvant TACE in HCC With High-risk Recurrence Factors","status":"RECRUITING","sponsor":"Guangxi Medical University","startDate":"2026-02-01","conditions":"Hepatocellular Carcinoma, Adjuvant, Transarterial Chemoembolization","enrollment":442},{"nctId":"NCT07380633","phase":"PHASE2","title":"Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-23","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":90},{"nctId":"NCT06199232","phase":"NA","title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University","startDate":"2024-01-23","conditions":"Liver Metastasis Colon Cancer, ctDNA Genotype, MSS","enrollment":47},{"nctId":"NCT07368023","phase":"","title":"A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Ningbo Medical Center Lihuili Hospital","startDate":"2026-01-25","conditions":"Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT07309419","phase":"PHASE2, PHASE3","title":"A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-22","conditions":"Hepatocellular Carcinoma","enrollment":222},{"nctId":"NCT06626516","phase":"PHASE1, PHASE2","title":"Tebentafusp-tebn With LDT in Metastatic UM","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-15","conditions":"Metastatic Uveal Melanoma","enrollment":109},{"nctId":"NCT07204262","phase":"","title":"Trajectory-Based Prognostic Modeling in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Xu Yong, MD","startDate":"2018-01-01","conditions":"Liver Cancer","enrollment":379},{"nctId":"NCT07187284","phase":"PHASE1, PHASE2","title":"EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2025-09-30","conditions":"HCC - Hepatocellular Carcinoma","enrollment":62},{"nctId":"NCT07062380","phase":"","title":"AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-10","conditions":"Hepatecellular Carcinoma, Hepatectomy","enrollment":353},{"nctId":"NCT07138885","phase":"PHASE2","title":"A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Hepatocellular Carcinoma (HCC), Second Line Treatment","enrollment":62},{"nctId":"NCT06323382","phase":"","title":"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab","enrollment":240},{"nctId":"NCT06031285","phase":"PHASE2","title":"Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-09-01","conditions":"Hepatocellular Carcinoma","enrollment":43},{"nctId":"NCT06643208","phase":"","title":"D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC","status":"RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2024-07-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":37},{"nctId":"NCT07009470","phase":"NA","title":"A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-02-10","conditions":"HCC","enrollment":130},{"nctId":"NCT05660213","phase":"","title":"A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":750},{"nctId":"NCT06904183","phase":"PHASE2","title":"Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-04-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":320},{"nctId":"NCT01792934","phase":"NA","title":"Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2013-05","conditions":"Multi-organ Metastatic Colorectal Cancer","enrollment":478},{"nctId":"NCT06641713","phase":"","title":"HAIC Compared With TACE in Huge Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-01","conditions":"Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer","enrollment":664},{"nctId":"NCT06038552","phase":"","title":"Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2002-01-01","conditions":"GIST, Malignant, Liver Metastases","enrollment":238},{"nctId":"NCT06397235","phase":"PHASE2","title":"DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-05-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":130},{"nctId":"NCT06823050","phase":"","title":"A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC","status":"NOT_YET_RECRUITING","sponsor":"Xuhua Duan","startDate":"2025-03-01","conditions":"Hepatocellular Carcinoma","enrollment":59},{"nctId":"NCT05920863","phase":"PHASE2","title":"Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-07-01","conditions":"Hepatocellular Carcinoma, Lenvatinib, Tislelizumab","enrollment":35},{"nctId":"NCT06492395","phase":"PHASE3","title":"Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":178},{"nctId":"NCT03812874","phase":"PHASE1, PHASE2","title":"A Study of PTX-9908 Injection for Non-resectable HCC with TACE","status":"RECRUITING","sponsor":"TCM Biotech International Corp.","startDate":"2020-10-06","conditions":"Carcinoma, Hepatocellular","enrollment":50},{"nctId":"NCT06699524","phase":"","title":"Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shen Feng","startDate":"2022-09-20","conditions":"Hepatocellular Carcinoma","enrollment":122},{"nctId":"NCT02856126","phase":"PHASE3","title":"HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-08","conditions":"Hepatocellular Carcinoma","enrollment":214},{"nctId":"NCT04799548","phase":"PHASE2","title":"A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-12-30","conditions":"Advanced Gastric Cancer","enrollment":71},{"nctId":"NCT05263219","phase":"PHASE3","title":"DEB-TACE+HAIC vs. HAIC for Large HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2022-02-10","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":230},{"nctId":"NCT05582278","phase":"PHASE2","title":"HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC","status":"UNKNOWN","sponsor":"Wen Li","startDate":"2021-01-01","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT05171335","phase":"PHASE2","title":"Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients","status":"ENROLLING_BY_INVITATION","sponsor":"The Methodist Hospital Research Institute","startDate":"2022-06-20","conditions":"Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT05247996","phase":"NA","title":"TACE Combined With \"Target Immune\" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-03-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":98},{"nctId":"NCT05233358","phase":"NA","title":"HAIC Combined With Second-line \"Target Immunity\" for HCC With TACE Standard Treatment Low Response or Failure","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-02-01","conditions":"Hepatocellular Carcinoma","enrollment":176},{"nctId":"NCT05135364","phase":"PHASE2","title":"HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure","status":"UNKNOWN","sponsor":"Yue Han","startDate":"2021-11-05","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":48},{"nctId":"NCT04479527","phase":"PHASE2","title":"Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-04","conditions":"Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT02908165","phase":"PHASE2","title":"Randomized Phase II Trial of Chemoembolization and Sorafenib","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2016-06","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT03274427","phase":"PHASE3","title":"Treatment of Intermediate-stage Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2017-07-18","conditions":"HCC","enrollment":300},{"nctId":"NCT00493402","phase":"PHASE3","title":"Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2007-07","conditions":"Hepatocellular Carcinoma","enrollment":365}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Transarterial Chemoembolization","TAE","Trans-Arterial Chemoembolization","Atezolizumab","Bevacizumab"],"phase":"phase_3","status":"active","brandName":"TACE regimen","genericName":"TACE regimen","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TACE (transarterial chemoembolization) is a locoregional therapy that delivers chemotherapy directly to hepatocellular carcinoma tumors via the hepatic artery while simultaneously blocking blood supply to the tumor. Used for Hepatocellular carcinoma, intermediate stage (BCLC stage B), Hepatocellular carcinoma, advanced stage (BCLC stage C) as bridge or palliative therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}